These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
365 related articles for article (PubMed ID: 15162486)
1. Probing flexibility and "induced-fit" phenomena in aldose reductase by comparative crystal structure analysis and molecular dynamics simulations. Sotriffer CA; Krämer O; Klebe G Proteins; 2004 Jul; 56(1):52-66. PubMed ID: 15162486 [TBL] [Abstract][Full Text] [Related]
2. Virtual screening for inhibitors of human aldose reductase. Kraemer O; Hazemann I; Podjarny AD; Klebe G Proteins; 2004 Jun; 55(4):814-23. PubMed ID: 15146480 [TBL] [Abstract][Full Text] [Related]
3. Evidence for a novel binding site conformer of aldose reductase in ligand-bound state. Steuber H; Zentgraf M; La Motta C; Sartini S; Heine A; Klebe G J Mol Biol; 2007 May; 369(1):186-97. PubMed ID: 17418233 [TBL] [Abstract][Full Text] [Related]
4. High-resolution crystal structure of aldose reductase complexed with the novel sulfonyl-pyridazinone inhibitor exhibiting an alternative active site anchoring group. Steuber H; Zentgraf M; Podjarny A; Heine A; Klebe G J Mol Biol; 2006 Feb; 356(1):45-56. PubMed ID: 16337231 [TBL] [Abstract][Full Text] [Related]
5. Ultrahigh resolution drug design I: details of interactions in human aldose reductase-inhibitor complex at 0.66 A. Howard EI; Sanishvili R; Cachau RE; Mitschler A; Chevrier B; Barth P; Lamour V; Van Zandt M; Sibley E; Bon C; Moras D; Schneider TR; Joachimiak A; Podjarny A Proteins; 2004 Jun; 55(4):792-804. PubMed ID: 15146478 [TBL] [Abstract][Full Text] [Related]
6. FlexE: efficient molecular docking considering protein structure variations. Claussen H; Buning C; Rarey M; Lengauer T J Mol Biol; 2001 Apr; 308(2):377-95. PubMed ID: 11327774 [TBL] [Abstract][Full Text] [Related]
7. Ultrahigh resolution drug design. II. Atomic resolution structures of human aldose reductase holoenzyme complexed with Fidarestat and Minalrestat: implications for the binding of cyclic imide inhibitors. El-Kabbani O; Darmanin C; Schneider TR; Hazemann I; Ruiz F; Oka M; Joachimiak A; Schulze-Briese C; Tomizaki T; Mitschler A; Podjarny A Proteins; 2004 Jun; 55(4):805-13. PubMed ID: 15146479 [TBL] [Abstract][Full Text] [Related]
8. The alrestatin double-decker: binding of two inhibitor molecules to human aldose reductase reveals a new specificity determinant. Harrison DH; Bohren KM; Petsko GA; Ringe D; Gabbay KH Biochemistry; 1997 Dec; 36(51):16134-40. PubMed ID: 9405046 [TBL] [Abstract][Full Text] [Related]
9. Structure of human aldose reductase holoenzyme in complex with statil: an approach to structure-based inhibitor design of the enzyme. El-Kabbani O; Ramsland P; Darmanin C; Chung RP; Podjarny A Proteins; 2003 Feb; 50(2):230-8. PubMed ID: 12486717 [TBL] [Abstract][Full Text] [Related]
10. The crystallographic structure of the aldose reductase-IDD552 complex shows direct proton donation from tyrosine 48. Ruiz F; Hazemann I; Mitschler A; Joachimiak A; Schneider T; Karplus M; Podjarny A Acta Crystallogr D Biol Crystallogr; 2004 Aug; 60(Pt 8):1347-54. PubMed ID: 15272156 [TBL] [Abstract][Full Text] [Related]
11. Aldose and aldehyde reductases: structure-function studies on the coenzyme and inhibitor-binding sites. El-Kabbani O; Old SE; Ginell SL; Carper DA Mol Vis; 1999 Sep; 5():20. PubMed ID: 10493777 [TBL] [Abstract][Full Text] [Related]
12. Structure-based optimization of aldose reductase inhibitors originating from virtual screening. Eisenmann M; Steuber H; Zentgraf M; Altenkämper M; Ortmann R; Perruchon J; Klebe G; Schlitzer M ChemMedChem; 2009 May; 4(5):809-19. PubMed ID: 19301313 [TBL] [Abstract][Full Text] [Related]
13. Expect the unexpected or caveat for drug designers: multiple structure determinations using aldose reductase crystals treated under varying soaking and co-crystallisation conditions. Steuber H; Zentgraf M; Gerlach C; Sotriffer CA; Heine A; Klebe G J Mol Biol; 2006 Oct; 363(1):174-87. PubMed ID: 16952371 [TBL] [Abstract][Full Text] [Related]
14. Structural features of the aldose reductase and aldehyde reductase inhibitor-binding sites. El-Kabbani O; Wilson DK; Petrash M; Quiocho FA Mol Vis; 1998 Sep; 4():19. PubMed ID: 9756955 [TBL] [Abstract][Full Text] [Related]
15. Computational sampling of a cryptic drug binding site in a protein receptor: explicit solvent molecular dynamics and inhibitor docking to p38 MAP kinase. Frembgen-Kesner T; Elcock AH J Mol Biol; 2006 May; 359(1):202-14. PubMed ID: 16616932 [TBL] [Abstract][Full Text] [Related]
16. Protein structure-based de novo design and synthesis of aldose reductase inhibitors. Iwata Y; Naito S; Itai A; Miyamoto S Drug Des Discov; 2001; 17(4):349-59. PubMed ID: 11765138 [TBL] [Abstract][Full Text] [Related]
17. Structural and thermodynamic study on aldose reductase: nitro-substituted inhibitors with strong enthalpic binding contribution. Steuber H; Heine A; Klebe G J Mol Biol; 2007 May; 368(3):618-38. PubMed ID: 17368668 [TBL] [Abstract][Full Text] [Related]
18. Validation of an automated procedure for the prediction of relative free energies of binding on a set of aldose reductase inhibitors. Ferrari AM; Degliesposti G; Sgobba M; Rastelli G Bioorg Med Chem; 2007 Dec; 15(24):7865-77. PubMed ID: 17870536 [TBL] [Abstract][Full Text] [Related]
19. Structure of aldehyde reductase holoenzyme in complex with the potent aldose reductase inhibitor fidarestat: implications for inhibitor binding and selectivity. El-Kabbani O; Carbone V; Darmanin C; Oka M; Mitschler A; Podjarny A; Schulze-Briese C; Chung RP J Med Chem; 2005 Aug; 48(17):5536-42. PubMed ID: 16107153 [TBL] [Abstract][Full Text] [Related]
20. Docking and molecular dynamics studies toward the binding of new natural phenolic marine inhibitors and aldose reductase. Wang Z; Ling B; Zhang R; Suo Y; Liu Y; Yu Z; Liu C J Mol Graph Model; 2009 Sep; 28(2):162-9. PubMed ID: 19616461 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]